Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM892JF)

Drug Name
Alpha-methyl-alpha-phenylsuccinimide (MPS) Drug Info
Synonyms
2-Methyl-2-phenylsuccinimide; 1497-17-2; 3-methyl-3-phenylpyrrolidine-2,5-dione; alpha-Methyl-alpha-phenylsuccinimide; N-Desmethylmethsuximide; Normesuximide; 2,5-Pyrrolidinedione, 3-methyl-3-phenyl-; a-methyl-a-phenylsuccinimide; N-Demethylmethsuximide; UDESUGJZUFALAM-UHFFFAOYSA-N; 3-Methyl-3-phenyl-2,5-pyrrolidinedione; .alpha.-Methyl-.alpha.-phenylsuccinimide; Normethsuximide; N-Normethsuximide; Desmethylmethsuximide; EINECS 216-091-7; Mesuximide, M(nor-); AC1Q6LV6; AC1L3NJ7; SCHEMBL1568276; UDESUGJZUFALAM-UHFFFAOYSA-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
92154
CAS Number
CAS 1497-17-2
TTD Drug ID
DM892JF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [2]
Ethosuximide DMDZ9LT Epilepsy 8A60-8A68 Approved [3]
Trimethadione DM0Q8MZ Absence epilepsy Approved [4]
Paramethadione DMR5ZUP Absence epilepsy Approved [4]
Methsuximide DM6L5VO Absence epilepsy Approved [1]
Penfluridol DMG1DTE Schizophrenia 6A20 Approved [5]
PD-200390 DMPW28M Insomnia 7A00-7A0Z Phase 2 [6]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [5]
ML218 DM3D21X Discovery agent N.A. Investigative [7]
KYS-05001 DM3MID9 Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Blocker [1]

References

1 Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
2 Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
3 Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
4 Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
5 Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
6 Pfizer. Product Development Pipeline. March 31 2009.
7 The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
8 Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.